Sol-Gel Technologies Ltd. (SLGL)
NASDAQ: SLGL · Real-Time Price · USD
0.4913
-0.0287 (-5.52%)
At close: Apr 1, 2025, 4:00 PM
0.5687
+0.0774 (15.75%)
After-hours: Apr 1, 2025, 4:25 PM EDT
Sol-Gel Technologies Revenue
Sol-Gel Technologies had revenue of $5.36M in the quarter ending September 30, 2024, with 2,416.90% growth. This brings the company's revenue in the last twelve months to $11.71M, up 869.93% year-over-year. In the year 2023, Sol-Gel Technologies had annual revenue of $1.55M, down -59.98%.
Revenue (ttm)
$11.71M
Revenue Growth
+869.93%
P/S Ratio
1.24
Revenue / Employee
$325,194
Employees
36
Market Cap
13.69M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.55M | -2.33M | -59.98% |
Dec 31, 2022 | 3.88M | -27.39M | -87.58% |
Dec 31, 2021 | 31.27M | 22.50M | 256.54% |
Dec 31, 2020 | 8.77M | -14.13M | -61.71% |
Dec 31, 2019 | 22.90M | 22.78M | 17,655.04% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SLGL News
- 4 months ago - Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 8 months ago - UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 8 months ago - Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 9 months ago - Sol-Gel Technologies Announces Management Realignment - GlobeNewsWire
- 11 months ago - Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 11 months ago - Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel - GlobeNewsWire
- 1 year ago - Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream - GlobeNewsWire
- 1 year ago - Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments - GlobeNewsWire